Publications

2019

Cross T, Ransegnola B, Shin J-, Weaver A, Fauntleroy K, VanNieuwenhze MS, et al. Spheroplast-Mediated Carbapenem Tolerance in Gram-Negative Pathogens. Antimicrob Agents Chemother. 2019;63(9).
Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, et al. Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. J Natl Compr Canc Netw. 2019;17(3):194-200.
Kobayashi S, Contractor T, Vosburgh E, Du Y-, Tang LH, Clausen R, et al. Alleles of Insm1 determine whether RIP1-Tag2 mice produce insulinomas or nonfunctioning pancreatic neuroendocrine tumors. Oncogenesis. 2019;8(3):16.
Gaudino MF, Lorusso R, Ohmes LB, Narula N, McIntire P, Gargiulo A, et al. Open radial artery harvesting better preserves endothelial function compared to the endoscopic approach. Interact Cardiovasc Thorac Surg. 2019;29(4):561-567.
Zadra G, Loda M. When fat goes down, prostate cancer is on the ropes. Mol Cell Oncol. 2019;6(3):1595308.
Navrazhina K, Hibler BP, Magro CM, Wildman HF. Beach Bummer: A Recurrent Pruritic Buttocks Eruption Following Travel. Am J Med. 2019;132(8):931-933.
Gomez-Arteaga A, Margolskee E, Wei MT, Van Besien K, Inghirami G, Horwitz S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019;60(7):1626-1631.
Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019;10(1):2977.
Martin P, Ruan J, Furman R, Rutherford S, Allan J, Chen Z, et al. A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leuk Lymphoma. 2019;60(12):2917-2921.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700